Gland Pharma moves up on getting USFDA’s tentative nod for Angiotensin II Injection

16 Nov 2023 Evaluate

Gland Pharma is currently trading at Rs. 1627.35, up by 9.40 points or 0.58% from its previous closing of Rs. 1617.95 on the BSE.

The scrip opened at Rs. 1610.05 and has touched a high and low of Rs. 1655.80 and Rs. 1610.05 respectively. So far 7881 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1914.00 on 29-Nov-2022 and a 52 week low of Rs. 861.50 on 22-May-2023.

Last one week high and low of the scrip stood at Rs. 1655.80 and Rs. 1597.05 respectively. The current market cap of the company is Rs. 26816.77 crore.

The promoters holding in the company stood at 57.86%, while Institutions and Non-Institutions held 27.36% and 14.78% respectively.

Gland Pharma has received tentative approval from the United States Food and Drug Administration (USFDA) for Angiotensin II Injection, 2.5 mg/mL Single Dose Vial. The company will launch the product with its marketing partner on receipt of final approval. The Angiotensin II Injection, 2.5 mg/mL Single Dose Vial (RLD: Giapreza Injection) has US sales of approximately $38 million for twelve months ending in September 2023, according to IQVIA.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.


Gland Pharma Share Price

1656.85 3.50 (0.21%)
29-Dec-2025 09:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1721.65
Dr. Reddys Lab 1269.00
Cipla 1513.65
Zydus Lifesciences 911.20
Lupin 2104.90
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×